Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease
S. Javad Sayedi (Mashhad, Islamic Republic of Iran), M. Reisi (Mashhad, Islamic Republic of Iran), M. Modaresi (Mashhad, Islamic Republic of Iran), Z. Aghaii (Mashhad, Islamic Republic of Iran), S. Mirlohi (Mashhad, Islamic Republic of Iran), H. Rafiemanesh (Mashhad, Islamic Republic of Iran), G. Azizi (Mashhad, Islamic Republic of Iran)
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Disease area: Airway diseases, Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Javad Sayedi (Mashhad, Islamic Republic of Iran), M. Reisi (Mashhad, Islamic Republic of Iran), M. Modaresi (Mashhad, Islamic Republic of Iran), Z. Aghaii (Mashhad, Islamic Republic of Iran), S. Mirlohi (Mashhad, Islamic Republic of Iran), H. Rafiemanesh (Mashhad, Islamic Republic of Iran), G. Azizi (Mashhad, Islamic Republic of Iran). Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease. 369
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020 Year: 2021
Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016
Doxycycline improves clinical outcomes during cystic fibrosis exacerbations Source: Eur Respir J , 49 (4) 1601102; DOI: 10.1183/13993003.01102-2016 Year: 2017
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016
Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Efficacy of long-acting bronchodilator inhalation on postoperative pulmonary function and quality of life in lung cancer patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Actual challenges in thoracic surgery Year: 2008
A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012
Inhaled glutathione tolerability and efficacy in patients with cystic fibrosis Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006
The efficacy and side-effects of varenicline in patients with mild to moderate chronic obstructive pulmonary diseases Source: Annual Congress 2010 - Passive smoking Year: 2010
The efficacy and tolerability of inhaled hypertonic saline in children with cystic fibrosis Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012
Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016